EU Signs 63m Euro Deal to Secure Supplies of COVID-19 Drug Remdesivir

European Union signs an agreement with Gilead Sciences Inc. for supplies of the company's antiviral medication called Remdesivir to treat the novel coronavirus.

The European Commission said that it had signed a 63 million-euro contract with American pharmaceutical company Gilead.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Batches of Remdesivir will be made available to the European Union member states and the UK from early August.’
Read More..

Tweet it Now

The distribution will be coordinated by the European Commission.

Remdesivir was the first medicine authorized at the EU level for treatment of COVID-19 after the European Commission fast-tracked the request for authorization earlier this month.

At the time, the media reported that the US had locked down all the production for July and 90 percent of it for August and September.

Coronavirus Drug Favipiravir To Be Sold Under Brand 'Ciplenza'
Cipla Ltd. on Friday said it has received regulatory approval from Drug Controller General of India to release Favipiravir in the country under the brand name ciplenza.

But EU Commissioner for Health and Food Safety Stella Kyriakides was upbeat about the drug reaching Europe.

"In recent weeks, the Commission has been working tirelessly with Gilead to reach an agreement to ensure that stocks of the first treatment authorized against COVID-19 are delivered to the EU," she said in the statement.

Possible Coronavirus Drug Identified: Study
Anti-parasitic drugs called Ivermectin, which is already available around the world can kill the coronavirus within 48 hours, reports a new study.

Kyriakides said the contract, funded by the Commission's Emergency Support Instrument, was signed on Tuesday, and thus would enable the provision of the medicine for the treatment of around 30,000 European patients presenting severe COVID-19 symptoms, helping cover the current needs.

The European Center for Disease Prevention and Control will be involved in the allocation at the EU level to ensure fair distribution.

Existing Drugs That Could Treat COVID-19 Discovered
Notably, four of these compounds were found to work synergistically with remdesivir, a current standard-of-care treatment for COVID-19, said new study.

The Commission said it was preparing a joint procurement for more supplies of the medicine for the period of October onwards.

Remdesivir is a treatment against COVID-19 for adults and adolescents as from age 12 with pneumonia who require supplemental oxygen.

Its producer, Gilead, must submit the final reports of the Remdesivir studies by December as part of the conditions to move from conditional marketing authorization to full marketing authorization.

Source-IANS